T1	p 96 145	nausea and vomiting after breast cancer surgery :
T2	p 218 270	Japanese patients . BACKGROUND Breast cancer surgery
T3	p 281 311	with the patient under general
T4	p 404 423	vomiting ( PONV ) .
T5	p 432 434	60
T6	p 449 496	patients who undergo mastectomy ( with axillary
T7	p 654 684	women who undergo mastectomy .
T8	p 881 925	breast cancer surgery in Japanese patients .
T9	p 1011 1030	Japanese women were
T10	p 1045 1046	1
T11	p 1691 1822	total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg ) were included in the study .
T12	p 1834 1863	group comprised 25 patients .
T13	p 2753 2805	Japanese women who underwent breast cancer surgery .
T14	i 20 41	propofol , droperidol
T15	i 48 62	metoclopramide
T16	i 190 208	placebo-controlled
T17	i 312 322	anesthesia
T18	i 470 480	mastectomy
T19	i 488 509	axillary dissection )
T20	i 526 527	.
T21	i 556 564	propofol
T22	i 570 581	subhypnotic
T23	i 624 631	placebo
T24	i 754 770	subhypnotic dose
T25	i 774 846	propofol with the conventional antiemetics droperidol and metoclopramide
T26	i 984 1002	placebo-controlled
T27	i 1073 1299	administration of propofol 0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture . A standard general anesthetic technique , including sevoflurane and air
T28	i 1303 1309	oxygen
T29	i 2070 2078	propofol
T30	i 2105 2115	droperidol
T31	i 2146 2160	metoclopramide
T32	i 2188 2195	placebo
T33	i 2296 2304	propofol
T34	i 2325 2335	droperidol
T35	i 2342 2365	propofol and droperidol
T36	i 2441 2455	metoclopramide
T37	i 2643 2655	propofol 0.5
T38	i 2662 2691	and droperidol 20 microg/kg 0
T39	i 2710 2720	anesthesia
T40	i 2860 2883	propofol and droperidol
T41	i 2898 2936	metoclopramide 0.2 mg/kg and placebo .
T42	o 96 115	nausea and vomiting
T43	o 379 412	postoperative nausea and vomiting
T44	o 740 748	efficacy
T45	o 1549 1572	extrapyramidal symptoms
T46	o 1591 1600	integrity
T47	o 1950 1962	demographics
T48	o 1965 2023	surgery type , or awakening time . The prevalences of PONV
T49	o 2240 2258	prevalence of PONV
T50	o 2407 2426	prevalences of PONV
T51	o 2501 2524	Extrapyramidal symptoms
T52	o 2597 2601	PONV
T53	o 2825 2829	PONV